12.54
-2.03%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenzhen Kangtai Biological Products Co
Its shares trade on Shenzhen under the ticker 300601.SZ. It has been listed since 7 February 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.67bn and net income of CN¥70.3m. At that date it held total assets of CN¥14.10bn and shareholders' equity of CN¥9.63bn.
Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2017-02-07. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The firm operates its businesses primary in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Feb 2017
- Employees
- 2,018
- Website
- biokangtai.com ↗
Leadership
Pay as last reported
- Mr. Weimin DuChairman of the Board, since 2008CN¥3.5m
- Mr. Xiang MiaoPresident, DirectorCN¥3.5m
- Mr. Anlong XuVice Chairman of the Board, since 2025
- Mr. Jianying MaChief Financial Officer
- Ms. Jin TaoVice President, Secretary of the BoardCN¥1.2m
- Mr. Jiankai LiuVice President, Director, since 2008CN¥3.0m
- Mr. Jianhui GanVice President, since 2025CN¥952,700
- Mr. Xiaoqi NieVice President
- Mr. Bing YuVice President
- Mr. Guanghui LiStaff Elected Director
- Mr. Keping HuIndependent DirectorCN¥150,000
- Mr. Jiaoyu LiIndependent DirectorCN¥150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 59
- Social
- 78
- Governance
- 39
- Direct emissions (scope 1)
- 19,829.65 t
- Energy emissions (scope 2)
- 86,228.19 t
- Women in the workforce
- 37.69%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenzhen Kangtai Biological Products Co Ltd employs 2,018 full-time employees in vaccine R&D and manufacturing.
- The company's main products include recombinant hepatitis B virus and haemophilus influenzae type b combined vaccine.
- Shenzhen Kangtai operates primarily in the domestic Chinese market for vaccine sales.
Weaknesses
- The company's business is primarily limited to the domestic Chinese market with no international expansion mentioned.
- Shenzhen Kangtai has no mention of international partnerships or global distribution channels.
- The company's product range focuses on specific vaccines without broader portfolio diversification.
Opportunities
- The domestic Chinese market offers significant growth potential for vaccine demand.
- Shenzhen Kangtai could expand into international markets for vaccine sales.
- Increasing global health initiatives may boost demand for the company's vaccines.
Threats
- The domestic market reliance poses a risk if Chinese vaccine regulations change.
- Competition from other Chinese vaccine manufacturers could intensify.
- Regulatory changes in China might affect vaccine manufacturing and sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.